Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases. (cellcol)
Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases That Are Going to be Submitted to a Major Liver Resection
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28031
- Hospital Clinico San Carlos
-
Madrid, Spain, 28040
- Alejandra Garcia Botella
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Men and women between ≥ 18 years and ≤ 80. Women in fertile age should use contraceptive methods recommended by the Clinical Trial Facilitation Group (CTFG).
- ECOG (Eastern Cooperative Oncology Group) quality of life scale ≤ 2.
Patients with hepatic metastases of colorectal carcinoma and insufficient hepatic remnant function to perform a major hepatectomy. This volume would be calculated by Positron emission tomography-Computed tomography (PET-CT) images or 64-channel multidetector CT.
In patients who have received preoperative chemotherapy, the estimate residual liver volume to be included in the study will be <40%.
Patients who have preserved liver function (Child ≤ B7 and International Normalized Ratio (INR) ≤ 2 in non-anticoagulated patients) and those who have not received chemotherapy, needs < 30% of residual volume to be included in the study.
- Patients should have signed informed consent.
Exclusion criteria:
- Pregnancy or lactation period.
- Any condition that the investigators consider an unjustifiable risk in the patient.
- Severe comorbidities: American Society of Anesthesiologists (ASA) ≥ 4.
- Alterations in the hemogram and morphological alterations, evaluated by hematologist prior to administration of G-CSF.
- Liver function: Child ≥ B7 and INR ≥ 2 in non-anticoagulated patients. In anticoagulated patients the values will have to be reverse, prior to surgery.
- Patients who have not received research drugs in the last 30 days or in the period of 5 elimination half-life.
- In patients on chemotherapy treatment, G-CSF can not be administered until 48 hours after the last administration of chemotherapy. Patients who have received Bevacizumab must wait 30 days since the last administration.
- In addition, all those aspects that prevent the patient from being part of the study, understand the rules, follow the instructions given, or other aspects.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PVE + CD133
preop portal vein embolization + stem cells infusion
|
Infusion of cells cd133+
portal vein embolization
|
|
Sham Comparator: PVE
only preop portal vein embolization
|
portal vein embolization
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Liver volume
Time Frame: once residual liver volume reach >40%, an average of 5 weeks.
|
Liver volume estimated by computed tomography
|
once residual liver volume reach >40%, an average of 5 weeks.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Liver volume
Time Frame: Post-surgery follow-up visits the first 30 days
|
Liver volume estimated by computed tomography
|
Post-surgery follow-up visits the first 30 days
|
|
Liver volume
Time Frame: Post-surgery follow-up visits the first 90 days
|
Liver volume estimated by computed tomography
|
Post-surgery follow-up visits the first 90 days
|
|
Liver volume
Time Frame: Post-surgery follow-up visits the first 180 days
|
Liver volume estimated by computed tomography
|
Post-surgery follow-up visits the first 180 days
|
|
Liver volume
Time Frame: Post-surgery follow-up visits the first 12 months
|
Liver volume estimated by computed tomography
|
Post-surgery follow-up visits the first 12 months
|
|
Liver volume
Time Frame: Post-surgery follow-up visits the first 18 months
|
Liver volume estimated by computed tomography
|
Post-surgery follow-up visits the first 18 months
|
|
Liver volume
Time Frame: Post-surgery follow-up visits the first 24 months
|
Liver volume estimated by computed tomography
|
Post-surgery follow-up visits the first 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2014-001402-18
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.